" /> Multiple endocrine neoplasia, type I - CISMeF





Preferred Label : Multiple endocrine neoplasia, type I;

Symbol : MEN1;

CISMeF acronym : MEN1;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : Men I; Endocrine adenomatosis, multiple; Mea I; Wermer syndrome;

Included titles and symbols : Men1 somatic mutations;

Description : Multiple endocrine neoplasia type I (MEN1) is an autosomal dominant disorder characterized by varying combinations of tumors of parathyroids, pancreatic islets, duodenal endocrine cells, and the anterior pituitary, with 94% penetrance by age 50. Less commonly associated tumors include foregut carcinoids, lipomas, angiofibromas, thyroid adenomas, adrenocortical adenomas, angiomyolipomas, and spinal cord ependymomas. Except for gastrinomas, most of the tumors are nonmetastasizing, but many can create striking clinical effects because of the secretion of endocrine substances such as gastrin, insulin, parathyroid hormone, prolactin, growth hormone, glucagon, or adrenocorticotropic hormone (summary by Chandrasekharappa et al., 1997). - Genetic Heterogeneity of Multiple Endocrine Neoplasia Other forms of multiple endocrine neoplasia include MEN2A (171400) and MEN2B (162300), both of which are caused by mutation in the RET gene (164761), and MEN4 (610755), which is caused by mutation in the CDKN1B gene (600778).;

Inheritance : Autosomal dominant;

Molecular basis : Caused by mutations in the menin gene (MEN1, 131100.0001);

Neoplasia : Carcinoid tumors;

Laboratory abnormalities : Elevated ACTH; Abnormal secretin test; Elevated gastrin concentration; Hypercalcemia; Hypoglycemia; Elevated PTH (parathyroid hormone);

Prefixed ID : #131100;

Details


You can consult :


Nous contacter.
28/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.